CJC-1295
Growth hormone releasing hormone analog — stimulates natural GH production.
What Is CJC-1295?
CJC-1295 is a modified version of growth hormone-releasing hormone (GHRH) — the signal your hypothalamus naturally sends to tell your pituitary to release growth hormone. The synthetic version is longer-lasting and more stable than its natural counterpart, making it a popular subject in GH secretagogue research. Unlike synthetic GH itself, CJC-1295 works by stimulating your body's own GH production, which means the feedback loops that prevent runaway hormone levels stay intact. The version stocked here is CJC-1295 without DAC (also called Modified GRF 1-29), designed for pulse-dosing protocols that closely mimic the natural rhythm of GH release.
The downstream effects of elevated GH — increased IGF-1 production, improved fat metabolism, enhanced muscle protein synthesis, and better sleep architecture — are what draw researchers to CJC-1295 in body composition and recovery protocols. Because it works through your own pituitary rather than introducing exogenous hormones, it preserves the natural GH feedback system in a way that direct GH administration does not. Paired with a GHSR agonist like Ipamorelin, CJC-1295 forms one of the most studied and widely cited dual-pathway GH secretagogue combinations in the research peptide space.
🔬 Mechanism of Action
CJC-1295 works upstream of growth hormone itself — which is what makes it mechanistically interesting. It binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating adenylyl cyclase activity and cAMP accumulation, which triggers GH synthesis and secretion. The result is elevated circulating GH that mirrors the body's natural pulsatile pattern rather than the supraphysiological spike you'd get from injecting exogenous GH. This distinction matters: natural pulsatile GH release preserves somatostatin feedback, the built-in brake that prevents overstimulation. The no-DAC version stocked here has a half-life of roughly 30 minutes, which is ideal for pulse-dosing protocols designed to synchronize with natural GH secretion windows — typically fasted states and the pre-sleep period when endogenous GH peaks are highest. Downstream of GH secretion, the liver responds by producing IGF-1 (insulin-like growth factor 1), which mediates most of GH's anabolic effects on skeletal muscle, adipose tissue, and bone. Rising IGF-1 is the practical biomarker researchers use to confirm that CJC-1295 is producing meaningful GH axis activation.
Effectiveness Profile
Relative effectiveness scores derived from published preclinical literature across key endpoints.
Scores are qualitative aggregates from animal and in vitro studies and are not a medical claim. For educational purposes only.
Applications & Benefits
Key Study Findings
Human pharmacokinetic studies confirmed sustained GH elevation for over 7 days with the DAC form — the longest documented duration for any GHRH analog
Dose-dependent IGF-1 increases documented in study subjects, confirming downstream hepatic GH signaling is intact and appropriately amplified
Pulsatile GH release pattern preserved with the no-DAC version — neuroendocrine feedback loops including somatostatin inhibition remain active, a key distinction from direct GH administration
Improved nitrogen retention and lean mass markers observed alongside IGF-1 elevation in research subjects, indicating functional downstream anabolic signaling
No-DAC form retains full GHRH receptor activity with a pulse-friendly 30-minute half-life, making it the preferred format for time-sensitive multi-dose GH secretagogue protocols
Synergistic GH output documented when CJC-1295 is combined with GHSR agonists like Ipamorelin — dual-pathway stimulation produces greater total GH release than either compound alone
Effect Timeline
Expected milestones based on published preclinical data.
First amplified GH pulses detected. Slight IGF-1 elevation begins; anabolic signaling pathways activate.
IGF-1 levels plateau at elevated baseline. Protein synthesis increases; recovery from training improves noticeably.
Lean mass accumulation measurable. Fat oxidation increases; sleep quality improvements typically reported.
Maximum body composition improvements at sustained elevated GH/IGF-1 levels. Anti-aging mechanisms fully engaged.
First amplified GH pulses detected. Slight IGF-1 elevation begins; anabolic signaling pathways activate.
IGF-1 levels plateau at elevated baseline. Protein synthesis increases; recovery from training improves noticeably.
Lean mass accumulation measurable. Fat oxidation increases; sleep quality improvements typically reported.
Maximum body composition improvements at sustained elevated GH/IGF-1 levels. Anti-aging mechanisms fully engaged.
Timelines are derived from preclinical animal studies. Individual results in laboratory settings may vary. For educational purposes only.
Dosing Protocol
Dosing information is derived from published animal studies and is provided for educational purposes only.
Reconstitution Calculator
Calculate exact BAC water volume and dose measurements for CJC-1295.
For laboratory use only. This calculator is a reference tool — verify all calculations before use. Always use sterile technique with bacteriostatic water and sterile syringes.
Synergistic Stack Combinations
Key Scientific Literature
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295
Key finding: Single injection of CJC-1295 produced dose-dependent GH increases lasting 6 days with IGF-1 elevation up to 28 days.
CJC-1295 increases GH and IGF-1 levels significantly
Key finding: Multiple doses showed cumulative IGF-1 increases of 20–30% maintained for up to 28 days post-injection.
Citations reference published peer-reviewed studies. This is not a complete literature review. All studies were conducted in preclinical or controlled clinical settings. Content is for educational reference only.
Frequently Asked Questions
Why choose CJC-1295 without DAC over the DAC version?
The no-DAC version (Modified GRF 1-29) is built for researchers who want to mimic the natural pulsatile rhythm of GH release. Because it clears the system in roughly 30 minutes, each dose triggers a discrete GH pulse — similar to how your body naturally releases GH in waves throughout the day. The DAC version's extended half-life (6–8 days) leads to continuous, tonic GH elevation, which some researchers argue disrupts the body's natural feedback rhythms. If you're designing a protocol around physiological GH patterns — especially when paired with a GHSR agonist like Ipamorelin — the no-DAC version is typically the preferred research tool.
How does CJC-1295 actually increase IGF-1 levels?
CJC-1295 stimulates GH release from the pituitary, and GH's primary downstream effect is signaling the liver to produce IGF-1 (insulin-like growth factor 1). IGF-1 is the hormone that mediates most of GH's anabolic effects — muscle protein synthesis, fat oxidation, bone density support. When you see IGF-1 levels rise in CJC-1295 studies, that's confirmation that the GH signal is being received and amplified through the hepatic axis. Researchers use IGF-1 as a practical biomarker for GH activity because it's easier to measure reliably than pulsatile GH itself.
Is stacking CJC-1295 with Ipamorelin actually synergistic, or just marketing?
There's a real mechanism behind it. CJC-1295 and Ipamorelin hit different receptors in the same pathway. CJC-1295 binds GHRH receptors on pituitary somatotrophs — the 'go' signal for GH release. Ipamorelin binds GHSR (the ghrelin receptor), which amplifies the magnitude of each GH pulse. Together, one compound provides the stimulus for GH release and the other amplifies the response, producing greater total GH output than either alone. Studies have documented this synergistic effect, which is why the CJC-1295 + Ipamorelin combination appears so consistently in growth hormone secretagogue research protocols.
What role does sleep timing play in CJC-1295 dosing protocols?
Sleep timing is one of the most discussed aspects of CJC-1295 without DAC protocols — and it's not arbitrary. The body's largest natural GH pulse occurs approximately 60–90 minutes after falling asleep, during the first wave of deep (slow-wave) sleep. Dosing CJC-1295 no-DAC 15–30 minutes before sleep is designed to amplify that natural pulse rather than create a separate, out-of-cycle GH spike. The idea is to work with the body's existing rhythm rather than impose an artificial pattern on top of it. Some researchers also include a fasted morning dose to catch a second natural GH window. This timing sensitivity is one of the main practical differences between the no-DAC and DAC versions — with the longer-acting DAC form, precise timing matters less.
💎CJC-1295 for Looksmaxxing
CJC-1295 is central to body recomposition looksmaxxing — the most studied GHRH analog for optimizing growth hormone output. In looksmaxxing protocols it's almost always paired with Ipamorelin to achieve synergistic GH pulse amplification. The resulting increases in GH and IGF-1 drive lean mass accretion, reduce fat mass (particularly visceral and subcutaneous), and improve skin quality through IGF-1-mediated collagen synthesis. It is the foundation of any appearance-focused growth hormone protocol.
Related Topics
CJC-1295
For educational use only · Verified vendor
